A first-in-human safety and early efficacy pilot study of TBX-3400
Latest Information Update: 12 Feb 2021
At a glance
- Drugs TBX-3400 (Primary)
- Indications Hepatitis B; Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Taiga Biotechnologies
- 12 Feb 2021 New trial record
- 09 Feb 2021 According to a Taiga Biotechnologies media release, this study was covered by the regulations of the Japanese Ministry of Health, Labour and Welfare.
- 09 Feb 2021 Results published in the Taiga Biotechnologies Media Release.